Zynerba Pharmaceuticals — Investor Presentation (January 2017)
37 slides from Zynerba Pharmaceuticals's investor presentation, Jan 6, 2017
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Company Highlights
Company Highlights 3 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory
Slide 3: Robust Pipeline
Robust Pipeline 4 ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 NDA Filing ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Epilepsy in Adults with Focal Seizures Osteoarthritis Fragile X Syndrome (US FDA Orphan
Slide 4: 2017 - A Transformational Year Ahead with Multiple Near-term Milestones
5 2017 - A Transformational Year Ahead with Multiple Near-term Milestones Expected Product Study Key Milestone Timing ZYN002 Epilepsy in Adults with Focal Seizures – STAR 1 Phase 2 Results July/August 2017 ZYN002 Osteoarthritis – STOP Phase 2 Results July/August 2017 ZYN002 Fragile X Syndrome – FAB-
Slide 5: ZYN002 – CBD Gel
ZYN002 – CBD Gel First and only patent-protected permeation-enhanced synthetic cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 6 CBD Delivery
Slide 6: Transdermal ZYN002 vs. Oral CBD
Transdermal ZYN002 vs. Oral CBD 7 Potential Benefits of Transdermal ZYN002 vs. Oral CBD More consistent, controlled and sustained plasma level Avoids first-pass metabolism in the liver Fewer drug-drug interactions Avoids the GI tract Very low incidence of gastrointestinal events Avoids degradation o
Slide 7: Transdermal CBD Avoids Degradation of CBD to THC
Transdermal CBD Avoids Degradation of CBD to THC 8 In Vitro Study ZYN002 avoids the GI tract, maintains CBD at physiological pH and prevents degradation of CBD to THC CBD degraded to THC in simulated gastric fluid May lead to increased psychoactive effects from THC Study data (Merrick et al.) publis
Slide 8: Phase 1 Trials Results for ZYN002
Trials 1 day, 7 day, and 14 day trials Subjects 98 healthy volunteers (n= 70 ZYN002; n= 28 placebo) and 22 epilepsy patients (n=16 ZYN002; n=6 placebo) Dose Daily doses levels – 50 to 504 mg CBD in 1%, 2.5% and 4.2% concentrations Safety & Tolerability ZYN002 was safe and well-tolerated at all dose
Slide 9: Why Are We Studying CBD in Epilepsy in Adults?
Why Are We Studying CBD in Epilepsy in Adults? 10 * Hauser WA Epilepsia. 1992, 4:S6-S14 CBD is effective in multiple animal models of epilepsy, which are highly predictive of efficacy in humans Kindling and maximal electroshock (models for focal and generalized seizures) Audiogenic, penicillin, pent
Slide 10: ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy Based on Other CBD Trials
ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy Based on Other CBD Trials 11 Lennox-Gastaut Syndrome Dravet Syndrome Refractory Epilepsy with Focal Seizures Type of Trial 2 Double Blind Placebo Controlled (3rd Party) Double Blind Placebo Controlled (3rd Party) STAR 1 and 2 – Un
Slide 11: Epilepsy Phase 2 Clinical Trial – STAR
Epilepsy Phase 2 Clinical Trial – STAR 12 ZYN002 High-Dose CBD 195 mg* ZYN002 Low-Dose CBD 97.5 mg* Placebo Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy *In 4.2% gel ZYN002 High-Dose CBD 195 mg* ZYN002 Low-Dose CBD 97.5 m
Slide 12: STAR Efficacy Endpoints
STAR 1 Efficacy Endpoints 13 Primary Endpoint: Median reduction in seizure frequency per 28-day period comparing baseline with the maintenance period via daily seizure diary Secondary Endpoints Proportion of patients with 50% reduction from baseline in seizure frequency Percent change from baseline
Slide 13: STAR Baseline Information
14 STAR 1 Baseline Information* Anti-Epileptic Drug Patients Anti-Epileptic Drug Patients Levetiracetam (Keppra) 48 Oxcarbazepine 17 Carabamazepine 41 Valproate 13 Lamotrigine 37 Clonazepam 12 Perampanel (Fycompa) 29 Zonisamide (Zonegran) 10 Lacosamide (Vimpat) 26 Phenytoin 4 Topiramate 18 Phenobarb
Slide 14: STAR Enrollment Status
15 STAR 1 Enrollment Status Patients n* Screened 201 Randomized 125 Completed 54 Enrolled into Star 2 50 * As of 5 January 2017
Slide 15: Why ZYN002 in Osteoarthritis?
Why ZYN002 in Osteoarthritis? 16 CBD modulates the vanilloid TRPV1 receptor which mediates antinociceptive and anti-inflammatory effects Mono-arthritic rat model provides proof of concept* ZYN002 was applied for four days after inducing arthritis in rats Significant reductions in: Swelling of knee j
Slide 16: Osteoarthritis Phase 2 Clinical Trial – STOP
Osteoarthritis Phase 2 Clinical Trial – STOP 17 Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis ZYN002 High-Dose: CBD 250 mg* ZYN002 Low-Dose: CBD 125 mg* Placebo Washout Baseline 1 week Every 12 hours for 12 weeks 7-10 days *In 4.2% gel Randomized (1:1:1), double-
Slide 17: STOP Efficacy Endpoints
STOP 1 Efficacy Endpoints 18 Primary Endpoint: Change from baseline in the weekly mean of the 24-hour average worst pain score at Week 12 Secondary Endpoints Assessments Change from baseline in the WOMAC Pain, Stiffness, and Physical Function Subscales Weeks 4, 8, 12 Responder rate based on 30% redu
Slide 18: STOP Baseline Information
19 STOP 1 Baseline Information* In recent OA placebo controlled studies, the worst knee pain during baseline has ranged from 6.1 to 6.7. Worst Knee Pain Score (During Baseline) Mean=6.7 *As of 5 January 2017
Slide 19: STOP Enrollment Status
20 STOP 1 Enrollment Status *As of 5 January 2017 Patients n* Screened 283 Randomized 189
Slide 20: What is Fragile X Syndrome?
What is Fragile X Syndrome? 21 Fragile X Syndrome Autism spectrum disorder Most common inherited intellectual disability Caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome Leads to dysregulation of the endocannabinoid pathway including the reduction in endogeno
Slide 21: Why ZYN002 in Fragile X Syndrome?
Why ZYN002 in Fragile X Syndrome? CBD may effectively treat Fragile X syndrome In mouse knock-out model, inhibition of the metabolism of 2-AG improves Fragile X syndrome symptoms CBD inhibits the metabolism of anandamide and 2-AG increasing availability of these cannabinoids CBD has strong anxiolyti
Slide 22: Fragile X Syndrome Phase 2 Clinical Trial - FAB–C
Fragile X Syndrome Phase 2 Clinical Trial - FAB – C 23 Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg* Daily Screening Titration Weeks 6 to 12 Day 1 to Week 6 Open label, doses of CBD 50 mg, 100 mg, or 250 mg* Daily *In 4.2% gel Target for enrollment is 16 patients Tre
Slide 23: FAB–C Outcome Measures
FAB – C Outcome Measures 24 Changes in Anxiety, Depression and Mood vs. Baseline as Measured by the ADAMS Scale Secondary Outcome Measures Aberrant Behavior Checklist Visual Analog Scale (VAS) to Assess Hyperactivity / Impulsivity Primary Outcome Measure
Slide 24: ZYN001 – THC Pro-Drug Patch
ZYN001 – THC Pro-Drug Patch 25 Patent-protected synthetic D-glyceric acid ester-9-tetrahydrocannabinol in a transdermal patch Working with LTS Lohmann Therapie-Systeme AG to optimize the formulation of ZYN001 for use in a state of the art drug-adhesive matrix transdermal patch before initiating phas
Slide 25: Why a Patch?
Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Why a Patch? 26 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controlled More consistent, contro
Slide 26: THC and neuropathic pain: third-party trial evidence
THC’s agonist effect on CB1 receptors modulates nociceptive thresholds by regulating neuronal activity Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN
Slide 27: ZYN001 – THC Pro-Drug Patch Status
ZYN001 – THC Pro-Drug Patch Status In vitro and in vivo studies to date show: Effective skin permeation with sustained delivery Non-mutagenic and non-genotoxic Safety pharmacology GLP studies Profile similar to THC GLP toxicology studies ongoing Working with LTS to optimize to a state of the art dru
Slide 28: ZYN001 – THC Pro-Drug Patch Preliminary Phase 1 Clinical Plan
ZYN001 – THC Pro-Drug Patch Preliminary Phase 1 Clinical Plan 30 Trial Patients Dosing PD Evaluations Timing Single Rising Dose Trial in Normal Subjects Pharmacokinetic profile and tolerability evaluation 32 healthy volunteers and 12 patients with fibromyalgia Single dose Cognition and attention (Tr
Slide 29: ZYN001 – THC Pro-Drug Patch Preliminary Phase 2 Clinical Plan
31 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionna
Slide 30: Cash Expected to Fund 5 Phase 3 Ready Programs
32 IPO August 2015 (NASDAQ: ZYNE) raised $42.1million, net Raised $9.5 million in net proceeds from the sale and issuance of 753,799 common shares through ATM from September 16 – November 11, 2016 at an average selling price of $13.38 Cash as of September 30, 2016 $31.8; no debt Includes $5.3 millio
Slide 31: A Compelling Investment Opportunity
A Compelling Investment Opportunity – Why Zynerba Could be the Next Explosive Growth Cannabinoid Company 33 We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy Third party studies have shown activity of CBD in redu
Slide 32: Proven Leadership in Transdermal Drug Development
Proven Leadership in Transdermal Drug Development 34 Armando Anido Chairman of the Board & Chief Executive Officer Terri Sebree President Jim Fickenscher CFO & VP Corp. Development Donna Gutterman, PharmD VP, Medical Nancy Tich, PhD VP, Clinical
Slide 33: Scientific Advisors
Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University M
Slide 34: Company Highlights
Company Highlights 36 A clinical-stage specialty pharmaceutical company pioneering the development of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in patch and gel transdermal delivery, regulatory
Slide 35: Investor Relations
Investor Relations 37 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Oppenheimer: Derek Archila H.C. Wainwright: Corey Davis, PhD Piper Jaffray: Charles C. Duncan, PhD Roth: Michael Higgins Canaccord Genuity: Arlinda Lee, PhD Cantor Fitzgerald: Elemer Piros, PhD * Note: Any opinions, esti
Slide 36: January 2017
January 2017 A clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs
Slide 37: ialty pharmaceutical
ialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs January 2017
Zynerba Pharmaceuticals — Investor Presentation (January 2017) on 6ix